For the year ending 2025-12-31, NVCT had $13,101K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -26,442 |
| Cost of share-based payments | 6,032 |
| Increase in other current assets | 1 |
| Increase/(decrease) in accounts payable | 3,776 |
| (decrease)/increase in accrued liabilities | -725 |
| Increase in employee compensation and benefits | 1,351 |
| Net cash used in operating activities | -16,009 |
| Proceeds from issuance of common shares-At Market Offering | 15,685 |
| Issuance costs-At Market Offering | 548 |
| Proceeds from issuance of common shares-Public Offering | 15,525 |
| Issuance costs-Public Offering | 1,552 |
| Net cash provided by financing activities | 29,110 |
| Increase/(decrease) in cash and cash equivalents | 13,101 |
| Cash and cash equivalents at beginning of period | 18,533 |
| Cash and cash equivalents at end of period | 31,634 |
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma, Inc. (NVCT)